| Id: | acc0208 |
| Group: | 2sens |
| Protein: | IRF-3 |
| Gene Symbol: | IRF3 |
| Protein Id: | Q14653 |
| Protein Name: | IRF3_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser396 |
| Site Sequence: | LENTVDLHISNSHPLSLTSDQ |
| Disease Category: | Cancer |
| Disease: | Medulloblastoma |
| Disease Subtype: | |
| Disease Cellline: | TE671 |
| Disease Info: | |
| Drug: | ISG15 OV |
| Drug Info: | "Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, used in the treatment of various cancers including melanoma, non-small cell lung cancer, and classical Hodgkin lymphoma. Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor used for the treatment of ovarian, breast, pancreatic, and prostate cancers with specific genetic mutations, such as BRCA1/2." |
| Effect: | modulate |
| Effect Info: | "Overexpression of ISG15 promotes the phosphorylation of IRF - 3 (Ser396), JAK2 (Tyr1007/1008) and STAT1 (Ser727), thereby reducing the cytopathic effect induced by JEV." |
| Note: | Non-conventional drugs |
| Score: | 3.0 |
| Pubmed(PMID): | 20035788 |
| Sentence Index: | 20035788_4-5 |
| Sentence: | "ISG15 over-expression in human medulloblastoma cells significantly reduced the JEV-induced cytopathic effect and inhibited JEV replication by reducing the viral titers and genomes (p<0.05, Student's t-test); it also increased activation of the interferon stimulatory response element (ISRE)-luciferase cis-acting reporter in JEV-infected cells (p<0.05, Chi-square test). Furthermore, Western blotting revealed that ISG15 over-expression increased phosphorylation of IRF-3 (Ser396), JAK2 (Tyr1007/1008) and STAT1 (Tyr701 and Ser727) in JEV-infected cells (P<0.05, Chi-square test)." |
Sequence & Structure:
MGTPKPRILPWLVSQLDLGQLEGVAWVNKSRTRFRIPWKHGLRQDAQQEDFGIFQAWAEATGAYVPGRDKPDLPTWKRNFRSALNRKEGLRLAEDRSKDPHDPHKIYEFVNSGVGDFSQPDTSPDTNGGGSTSDTQEDILDELLGNMVLAPLPDPGPPSLAVAPEPCPQPLRSPSLDNPTPFPNLGPSENPLKRLLVPGEEWEFEVTAFYRGRQVFQQTISCPEGLRLVGSEVGDRTLPGWPVTLPDPGMSLTDRGVMSYVRHVLSCLGGGLALWRAGQWLWAQRLGHCHTYWAVSEELLPNSGHGPDGEVPKDKEGGVFDLGPFIVDLITFTEGSGRSPRYALWFCVGESWPQDQPWTKRLVMVKVVPTCLRALVEMARVGGASSLENTVDLHISNSHPLSLTSDQYKAYLQDLVEGMDFQGPGES
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| IRF3-Ser175 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.27 | ||||
| HGSC | -1.433 | ||||
| ccRCC | |||||
| GBM | 0.895 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.269 | ||||
| IRF3-Thr180 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | |
| GBM | |
| HNSC | 0.581 |
| LUAD | 0.997 |
| LUSC | -0.328 |
| non_ccRCC | |
| PDAC | |
| UCEC | -1.249 |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| - | - | U | Alzheimer's disease | Phosphorylation | 36964897 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
